While USP7 involvement in tumorigenesis should be further investigated (e.g. in deep studying USP7 targeting miRNA(s) and regulation of CK2 enzymatic activity), our data attribute to USP7 inhibitors a therapeutic role in CLL precision medicine, functioning through the reactivation of the tumor suppressor PTEN. The gene discussed is USP7; the disease is B-cell chronic lymphocytic leukemia.